Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
3B Pharmaceuticals GmbH has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 examiners across 2 art units, creating examiner-specific issues within a relatively contained technical distribution.
BAEK, JONGHWAN NMN is the busiest examiner, with 1 pending matter. Because the pending actions are distributed among the examiners shown, counsel should maintain separate response analysis while checking for recurring technical themes across the art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAEK, JONGHWAN NMN | 1 | 50.0% | +0.0% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 35.0% | +35.4% |
| KOMATSU, LI N | 1 | 59.8% | +71.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18291078 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | BAEK, JONGHWAN NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270904 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 17571067 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | KOMATSU, LI N | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18291078 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | BAEK, JONGHWAN NMN | 1618 | §103§112 | Non-Final OA | — | Pending | Jan 22, 2024 |
| 18270904 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103§112DP | Non-Final OA | — | Pending | Jul 05, 2023 |
| 17571067 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | KOMATSU, LI N | 1658 | §112 | Non-Final OA | — | Pending | Jan 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial3B Pharmaceuticals GmbH has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Jonghwan Nmn Baek has the most, with 1 of 3B Pharmaceuticals GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
